i
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan
-
3 2024
-
-
Source: Emerg Infect Dis. 2024; 30(3):478-489
[PDF-5.13 MB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:Taiwan provided several COVID-19 vaccine platforms: mRNA (BNT162b2, mRNA-1273), adenoviral vector-based (AZD1222), and protein subunit (MVC-COV1901). After Taiwan shifted from its zero-COVID strategy in April 2022, population-based evaluation of vaccine effectiveness (VE) became possible. We conducted an observational cohort study of 21,416,151 persons to examine VE against SARS-CoV-2 infection, moderate and severe illness, and death during March 22, 2021-September 30, 2022. After adjusting for age and sex, we found that persons who completed 3 vaccine doses (2 primary, 1 booster) or received MVC-COV1901 as the primary series had the lowest hospitalization incidence (0.04-0.20 cases/100,000 person-days). We also found 95.8% VE against hospitalization for 3 doses of BNT162b2, 91.0% for MVC-COV1901, 81.8% for mRNA-1273, and 65.7% for AZD1222, which had the lowest overall VE. Our findings indicated that protein subunit vaccines provide similar protection against SARS-CoV-2---associated hospitalization as mRNA vaccines and can inform mix-and-match vaccine selection in other countries.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:38295401
-
Pubmed Central ID:PMC10902541
-
Document Type:
-
Place as Subject:
-
Volume:30
-
Issue:3
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
